10-Q: Cognition Therapeutics Reports Q2 2025 Results, Advances Clinical Pipeline

Cognition Therapeutics reported a reduced net loss in Q2 2025, highlighted positive Phase 2 clinical data for zervimesine in Alzheimer's and DLB, and secured funding for a DLB expanded access program, despite ongoing liquidity concerns and Nasdaq compliance challenges.

Summary

• Net loss for the six months ended June 30, 2025, was $15.2 million, an improvement from $16.2 million for the same period in 2024.
• Cash and cash equivalents decreased to $10.7 million as of June 30, 2025, from $25.0 million at December 31, 2024.
• Net cash used in operating activities increased to $15.5 million for the six months ended June 30, 2025, compared to $13.2 million for the same period in 2024.
• The company believes its current cash and cash equivalents are sufficient to fund operations into the second quarter of 2026, assuming no usage of At-The-Market (ATM) or Lincoln Park facilities.
• Substantial doubt exists about the company's ability to continue as a going concern.
• Phase 2 SHINE study (Alzheimer's) met primary safety endpoints; a prespecified analysis showed a 95% reduction in cognitive decline for a subgroup with low plasma p-tau217.
• Phase 2 SHIMMER study (Dementia with Lewy Bodies) met primary safety endpoints, with zervimesine-treated patients showing significant benefits across behavioral, functional, cognitive, and motor scales (e.g., 86% better on NPIA-L).
• Phase 2 MAGNIFY study (Geographic Atrophy) was voluntarily concluded, but reported 29% slower GA lesion growth and 28% smaller lesions at 18 months for zervimesine-treated participants compared to placebo.
• An anonymous philanthropic donation was received in June 2025 to substantially fund an Expanded Access Program (EAP) for DLB.
• The company sold 4,926,473 shares under its ATM sales agreement for gross proceeds of approximately $2.4 million during the six months ended June 30, 2025.
• As of June 30, 2025, $19.5 million remained available under the ATM and $34.8 million under the Lincoln Park equity line financing.
• The company faces a Nasdaq minimum bid price compliance deadline of September 8, 2025, after transferring to the Nasdaq Capital Market.

Sentiment

Score: 4

Explanation: While the clinical trial results for zervimesine are promising across multiple indications, particularly the strong data in DLB and the subgroup analysis in Alzheimer's, the company's severe liquidity issues, explicit going concern warning, and ongoing Nasdaq compliance challenges present significant financial instability. The positive clinical developments are overshadowed by the immediate need for substantial capital and the risk of delisting.

Positives

• Net loss decreased by $1.0 million for the six months ended June 30, 2025, compared to the same period in 2024.
• General and administrative expenses decreased by $1.2 million for the six months ended June 30, 2025, compared to the same period in 2024.
• Zervimesine (CT1812) demonstrated positive safety and tolerability across three Phase 2 studies (SHINE, SHIMMER, MAGNIFY).
• Phase 2 SHINE study showed a 95% reduction in cognitive decline in a prespecified subgroup of Alzheimer's patients with low plasma p-tau217.
• Phase 2 SHIMMER study showed significant benefits in DLB patients across multiple scales, including 86% better on NPIA-L and 52% better on ADCS-ADL compared to placebo.
• Phase 2 MAGNIFY study, despite early conclusion, reported 29% slower GA lesion growth and 28% smaller lesions at 18 months, comparable to approved complement inhibitors, with the advantage of oral administration and no CNV conversion risk.
• Secured an anonymous philanthropic donation in June 2025 to substantially fund an Expanded Access Program (EAP) for DLB.
• $41.9 million available from obligated NIA funds for future applicable expenses as of June 30, 2025.

Negatives

• Cash and cash equivalents significantly decreased to $10.7 million as of June 30, 2025, from $25.0 million at December 31, 2024.
• Net cash used in operating activities increased to $15.5 million for the six months ended June 30, 2025, from $13.2 million in the prior year period, indicating increased cash burn.
• Accumulated deficit reached $190.4 million as of June 30, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern.
• The overall modified intent-to-treat population in the SHINE study did not achieve statistical significance for cognitive decline slowing (38% slowing vs. placebo).
• The MAGNIFY study for Geographic Atrophy was voluntarily concluded early to reallocate resources, indicating a strategic shift away from this indication.
• 23 incidents (9.6%) of transient treatment-emergent liver enzyme test (LFT) increases greater than 3xULN were observed across zervimesine-treated participants in Phase 2 studies.
• The company failed to regain Nasdaq compliance by the initial deadline and faces an extended deadline of September 8, 2025, for the $1.00 minimum bid price requirement.

Risks

• Ability to raise additional capital to fund operations and continue product candidate development.
• Ability to continue as a going concern for the next twelve months.
• Ability to maintain the listing of common stock on the Nasdaq Capital Market, with a compliance deadline of September 8, 2025, for the $1.00 minimum bid price.
• Estimates regarding expenses, future revenue, capital requirements, and needs for additional financing may be inaccurate.
• The clinical nature of the business and ability to successfully and timely advance product candidates through clinical trials.
• Timing, scope, and likelihood of regulatory filings and approvals.
• Dependence on the success of zervimesine (CT1812), the lead product candidate.
• Challenges due to the novel nature of targeting the sigma-2 (S2R) receptor complex.
• Impact of changes in funding for, or disruptions to, the FDA and other government agencies, including potential government shutdowns or policy changes from the U.S. presidential administration in 2025.
• Reliance on third parties for manufacturing, packaging, labeling, storage, and distribution of product candidates.

Future Outlook

We expect to continue to incur significant and increasing expenses and net losses for the foreseeable future as we advance product candidates, seek regulatory approval, expand intellectual property, and hire personnel. We will need substantial additional funding, likely through equity offerings, debt financings, or collaborations, to support operations and growth, as we do not anticipate generating significant revenue from product sales until regulatory approval, if ever. We also expect to continue pursuing non-dilutive grants, including additional NIA funding.

Management Comments

• We believe that our cash and cash equivalents as of June 30, 2025 is not sufficient to fund operations for the period through one year after the date of this filing and therefore substantial doubt exists about the Company's ability to continue as a going concern.
• To execute our business plans, we will need substantial funding to support our continuing operations and pursue our growth strategy.
• We expect to continue to incur significant and increasing expenses and net losses for the foreseeable future, as we advance our current and future product candidates through preclinical and clinical development, manufacture drug product and drug supply, seek regulatory approval for our current and future product candidates, maintain and expand our intellectual property portfolio, hire additional research and development and business personnel and operate as a public company.
• We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for our product candidates.

Industry Context

The company operates in the highly competitive and challenging biopharmaceutical sector, focusing on age-related neurodegenerative diseases like Alzheimer's and DLB, and retinal disorders like geographic atrophy. Its lead candidate, zervimesine, targets the S2R complex, representing a novel mechanism distinct from many current approaches. The positive Phase 2 results for DLB and the subgroup analysis in Alzheimer's, along with the comparative efficacy in GA against approved complement inhibitors, position zervimesine as a potentially significant oral alternative in these markets, if further clinical development and regulatory approvals are successful. The voluntary conclusion of the MAGNIFY study indicates a strategic focus shift towards CNS disorders, which are areas of high unmet medical need.

Comparison to Industry Standards

• SHINE study results (38% slowing of cognitive decline in overall population) are comparable in magnitude to what was achieved with currently approved monoclonal antibody treatments for Alzheimer's disease.
• MAGNIFY study results (29% slower GA lesion growth, 28% smaller lesions at 18 months) are comparable to what was reported with currently approved complement inhibitors for geographic atrophy.
• Zervimesine offers the convenience of once-daily oral administration and no conversion from dry AMD to choroidal neovascularization (or CNV), which is a risk factor of treatment with intravitreal complement inhibitors.

Stakeholder Impact

• Shareholders face significant dilution risk from future capital raises, potential loss of investment if the company cannot secure funding or maintain Nasdaq listing, but also potential upside from successful clinical development.
• Employees' job security may be at risk due to going concern issues, but continued clinical progress offers hope for long-term stability.
• Patients and the medical community see potential for novel treatments for Alzheimer's, DLB, and GA, especially with the DLB EAP, but development is contingent on financial viability.
• Creditors face increased risk due to the company's liquidity challenges and going concern warning.
• Suppliers and Contract Research Organizations (CROs) depend on the company's ability to secure funding for ongoing and future clinical trials and manufacturing.

Next Steps

• Receive formal minutes from the End-of-Phase 2 meeting with the FDA (expected approximately 30 days after July 9, 2025).
• Advance zervimesine (CT1812) through ongoing and future clinical trials, preclinical studies, and development activities.
• Seek regulatory approvals for product candidates.
• Maintain and expand the intellectual property portfolio.
• Hire additional research and development and business personnel.
• Address the Nasdaq minimum bid price deficiency by September 8, 2025.
• Secure substantial additional funding through equity offerings, debt financings, or strategic collaborations.
• Continue pursuit of non-dilutive research contributions and grants.
• Initiate and enroll participants in the Expanded Access Program (EAP) for DLB.

Key Dates

Recommendation

Despite promising clinical data for zervimesine in multiple indications, the company's severe liquidity crisis, explicit "going concern" warning, and ongoing Nasdaq delisting threat create an extremely high-risk investment profile. The need for substantial additional capital, coupled with a history of losses and increasing cash burn, suggests significant future dilution or even potential insolvency. A seasoned investor would prioritize capital preservation given these fundamental financial risks, even with the clinical upside.

Keywords

Alzheimer's disease, Dementia with Lewy Bodies (DLB), Geographic Atrophy (GA), Zervimesine (CT1812), Biopharmaceutical, Clinical trials, Neurodegenerative diseases, Nasdaq compliance, Going concern, Biomarkers, Expanded Access Program (EAP), Sigma-2 (S2R) receptor